Loading...
•
Dec 31, 2021
Bio-Techne Q2 2022 Earnings Report
Bio-Techne's Q2 2022 earnings showcased strong growth, driven by operational excellence and strategic investments.
Key Takeaways
Bio-Techne reported a strong second quarter in fiscal year 2022, with a 20% increase in net sales to $269.3 million and organic revenue growth of 17%. The company's adjusted EPS increased to $1.88, and adjusted operating income rose by 18% to $102.8 million. The Protein Sciences segment demonstrated sustained operational excellence, achieving 19% organic growth.
Second quarter organic revenue increased by 17% (20% reported) to $269.3 million.
GAAP EPS was $1.94 versus $1.15 one year ago.
Adjusted EPS increased to $1.88 per diluted share, versus $1.62 in the same quarter last year.
Adjusted operating income for the second quarter of fiscal 2022 increased 18% compared to the second quarter of fiscal 2021.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Revenue by Segment
Protein Sciences Revenue
CapyFin.comDiagnostics & Spatial Bio Revenue
CapyFin.com Forward Guidance
The Wilson Wolf future investment and acquisition agreement signed in December has the potential to further extend the company's 2026 revenue target beyond $2 billion and positions its Cell and Gene Therapy workflow with the strongest global footprint in this exploding new market.